Skip to content

Jaesuk Yun

4 papers in the library · 14 citations · publishing 2022-2024

Papers

Prenatal ketamine exposure impairs prepulse inhibition via arginine vasopressin receptor 1A-mediated GABAergic neuronal dysfunction in the striatum.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie April 1, 2023 Aeseul Kim, Sun Mi Gu, Haemiru Lee et al. 5 citations

Prenatal exposure to NMDA receptor antagonists like ketamine and methoxetamine in pregnant rats leads to psychosis-like behaviors in their offspring, including hyperactivity and reduced prepulse inhibition (PPI), a measure of sensorimotor gating. These effects are linked to increased expression of the arginine vasopressin receptor 1A (Avpr1a) in the striatum, and artificially overexpressing Avpr1a in the striatum also impairs PPI. Additionally, the treatments raise levels of glutamate decarboxylase 67 (GAD67) and GABA in the striatum, indicating that prenatal NMDA receptor blockade disrupts GABAergic neuron function and sensorimotor gating through Avpr1a regulation.

Deletion of Cryab increases the vulnerability of mice to the addiction-like effects of the cannabinoid JWH-018 via upregulation of striatal NF-κB expression

Frontiers in Pharmacology March 16, 2023 Leandro Val Sayson, Darlene Mae Ortiz, Hyun Jun Lee et al. 4 citations

Mice lacking the Cryab gene show stronger addiction-like responses to the synthetic cannabinoid JWH-018, including greater self-administration and place preference, along with altered gamma brain waves, compared to normal mice. Repeated JWH-018 exposure did not change endocannabinoid or dopamine gene expression or dopamine levels in the brain's reward center between the two groups. However, the knockout mice displayed increased neuroinflammation, linked to upregulated NF-κB, and higher levels of synaptic plasticity markers. These findings suggest that heightened neuroinflammation via NF-κB may drive the enhanced cannabinoid addiction-related behaviors in Cryab knockout mice, making them a potential model for studying susceptibility to cannabinoid abuse.

Rewarding and reinforcing effects of two dissociative-based new psychoactive substances, deschloroketamine and diphenidine, in mice.

Pharmacology, biochemistry, and behavior February 1, 2022 Jin Mook Kim, Boreum Han, Hyun Kyu Min et al. 4 citations

Deschloroketamine (10 mg/kg) and diphenidine (10-60 mg/kg) produced increased locomotor activation and stereotypy similar to ketamine (10 mg/kg) in mice. Both substances increased preference for the drug-paired compartment in conditioned place preference testing, indicating rewarding effects. In self-administration tests, deschloroketamine (1 mg/kg/infusion) increased active lever presses and infusions, suggesting reinforcing effects, whereas diphenidine (1, 2 mg/kg/infusion) did not alter these measures. Both compounds increased dopamine levels in PC-12 cells. The data suggest deschloroketamine may have both rewarding and reinforcing effects, while diphenidine only induced rewarding effects.

Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.

Journal of veterinary science September 1, 2024 Sun Mi Gu, Eunchong Hong, Sowoon Seo et al. 1 citation

Reducing levels of the GABA-synthesis enzyme GAD67 in the dorsal striatum of mice increased depression-like behavior but decreased anxiety. The reduction also heightened the rewarding effect of ketamine, measured by conditioned place preference, but did not alter the reward behavior triggered by the cannabinoid agonist JWH-018. The findings suggest that lower striatal GAD67 weakens GABAergic signaling, which may make the brain more vulnerable to ketamine's reward effects by enhancing NMDA receptor inhibition.